Sign In
Buy FLDM
$1.83
+0 (+0%)
At Close: Jul 20, 2022
Fluidigm Corporation: Discounted Life Sciences Instrument Developer Offers Compelling Entry Point
02:10pm, Sunday, 20'th Jun 2021
Fluidigm Corporation is a leading global developer of life sciences instruments and consumables for use in research, diagnostics, and clinical applications. Fluidigm designs, manufactures, and markets
Next-Generation CyTOF XT Redefines Cytometry with Advances in Automation, Throughput, Time to Results and Total Cost of Ownership
02:00pm, Tuesday, 25'th May 2021
A New Platform to Simplify Deep Profiling of the Human Immune System A New Platform to Simplify Deep Profiling of the Human Immune System
FLAMIN-GO Project Seeks to Develop Organ-on-a-Chip Technology for Clinical Trials in Rheumatoid Arthritis Therapy FLAMIN-GO Project Seeks to Develop Organ-on-a-Chip Technology for Clinical Trials in R
Fluidigm to Present at Upcoming Investor Conferences
08:30am, Friday, 14'th May 2021
SOUTH SAN FRANCISCO, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health
FLDM Stock: 17.56% Increase Explanation
11:24pm, Tuesday, 11'th May 2021
The stock price of Fluidigm Corporation (NASDAQ: FLDM) increased by 17.56%. This is why it happened.
Fluidigm Announces Virtual Mass Cytometry Webinar Investor Event on May 24, 2021, at 1:00 p.m. Eastern Time
01:30pm, Monday, 10'th May 2021
SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health
Fluidigm Corporation's (FLDM) CEO Chris Linthwaite on Q1 2021 Results - Earnings Call Transcript
04:30pm, Sunday, 09'th May 2021
Fluidigm Corporation's (FLDM) CEO Chris Linthwaite on Q1 2021 Results - Earnings Call Transcript
Fluidigm: Q1 Earnings Insights
05:27pm, Thursday, 06'th May 2021
Shares of Fluidigm (NASDAQ:FLDM) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 15.38% year over year to ($0.15), which missed the e
Study Suggests Mass Cytometry Is a Valuable Tool for Predicting Individual Patient Response to Therapies Study Suggests Mass Cytometry Is a Valuable Tool for Predicting Individual Patient Response to
Fluidigm Announces Conference Call and Webcast of First Quarter 2021 Financial Results
08:30am, Thursday, 08'th Apr 2021
SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive heal
3 Extraordinary Diagnostics Stocks for 2021
07:33am, Sunday, 21'st Mar 2021
Innovation is risky, and these companies are all in.
Why Fluidigm Stock Is Sinking Today
11:40am, Thursday, 11'th Feb 2021
The company reported disappointing fourth-quarter results.
Fluidigm Corporation (FLDM) CEO Chris Linthwaite on Q4 2020 Results - Earnings Call Transcript
11:03pm, Wednesday, 10'th Feb 2021
Fluidigm Corporation (FLDM) CEO Chris Linthwaite on Q4 2020 Results - Earnings Call Transcript
Fluidigm (FLDM) Reports Q4 Loss, Misses Revenue Estimates
06:31pm, Wednesday, 10'th Feb 2021
Fluidigm (FLDM) delivered earnings and revenue surprises of -225.00% and -11.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
PLT and Fluidigm Collaborate on Submission to the National Medical Products Administration for a CyTOF Device Approved for Diagnostic Use in China PLT and Fluidigm Collaborate on Submission to the Nat
